Scholarlink

<p>Ovarian cancer has a poor clinical prognosis due to chemoresistance following carboplatin/paclitaxel treatment. This phenomenon can be explained by an imbalanced ratio of [anti-apoptotic (BCL-xL/MCL-1)] to [pro-apoptotic (Noxa, BIM, PUMA)] BCL-2 family members that prevents apoptosis initiation. Consequently, any treatment capable of counterbalancing this ratio could be beneficial in the management of ovarian cancer. Calcium signaling is strongly implicated in resistance to apoptosis, as it depends on, but also regulates, the expression of the ratio of BCL-2 family members, making calcium-targeted strategies relevant to overcoming chemoresistance. Knowing that SERCA2 calcium pumps regulation plays a major role in controlling the ER stress-induced UPR response that could lead to pro-apoptotic protein upregulation and cell death, we therefore evaluated whether their inhibition could elicit apoptosis or sensitize ovarian cancer cells to other therapeutic strategies. For this purpose, the platinum-resistant cell line, OAW42-R, was treated with anti-SERCA2 strategies which revert the BCL-2 family member expression ratio in favor of pro-apoptotic proteins. Combination with the BH3-mimetic ABT-737 exacerbates this imbalance not only by inhibiting BCL-xL activity but also through over-induction of the UPR/ATF4/Noxa axis, leading to MCL-1 inhibition. This dual effect of ABT-737 upon ER stress fully suppresses the anti-apoptotic capacities of cancer cells, leading to massive mitochondrial apoptosis. This point was supported with ONC201, the first member of the imipridone family of anticancer drugs to enter the clinic, whose ability to trigger UPR/ATF4/Noxa led to apoptosis commitment when it was combined with ABT-737 treatment. The therapeutic efficacy of these combinations was also proved in patient-derived tumor organoid models (PDTO), leading to their structural disintegration and reduced viability. Collectively, our study highlights that ABT-737, through BCL-xL inhibition and synergy with ER stress inducers, triggers ovarian cancer death, offering promising strategies for overcoming chemoresistance in relapsed ovarian cancer.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

UPR/ATF4/Noxa pathway overactivation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Sahra Messaoudi,
  • Romane Florent,
  • Louis-Bastien Weiswald,
  • Guillaume Desmartin,
  • Lucie Lecouflet,
  • Steven Lohard,
  • Léa Grunchec,
  • Edwige Abeilard,
  • Marilyne Guillamin,
  • Jordane Divoux,
  • Benoît Goudergues,
  • Emilie Brotin,
  • Enora Dolivet,
  • Laurent Poulain,
  • Monique N’Diaye

摘要

Ovarian cancer has a poor clinical prognosis due to chemoresistance following carboplatin/paclitaxel treatment. This phenomenon can be explained by an imbalanced ratio of [anti-apoptotic (BCL-xL/MCL-1)] to [pro-apoptotic (Noxa, BIM, PUMA)] BCL-2 family members that prevents apoptosis initiation. Consequently, any treatment capable of counterbalancing this ratio could be beneficial in the management of ovarian cancer. Calcium signaling is strongly implicated in resistance to apoptosis, as it depends on, but also regulates, the expression of the ratio of BCL-2 family members, making calcium-targeted strategies relevant to overcoming chemoresistance. Knowing that SERCA2 calcium pumps regulation plays a major role in controlling the ER stress-induced UPR response that could lead to pro-apoptotic protein upregulation and cell death, we therefore evaluated whether their inhibition could elicit apoptosis or sensitize ovarian cancer cells to other therapeutic strategies. For this purpose, the platinum-resistant cell line, OAW42-R, was treated with anti-SERCA2 strategies which revert the BCL-2 family member expression ratio in favor of pro-apoptotic proteins. Combination with the BH3-mimetic ABT-737 exacerbates this imbalance not only by inhibiting BCL-xL activity but also through over-induction of the UPR/ATF4/Noxa axis, leading to MCL-1 inhibition. This dual effect of ABT-737 upon ER stress fully suppresses the anti-apoptotic capacities of cancer cells, leading to massive mitochondrial apoptosis. This point was supported with ONC201, the first member of the imipridone family of anticancer drugs to enter the clinic, whose ability to trigger UPR/ATF4/Noxa led to apoptosis commitment when it was combined with ABT-737 treatment. The therapeutic efficacy of these combinations was also proved in patient-derived tumor organoid models (PDTO), leading to their structural disintegration and reduced viability. Collectively, our study highlights that ABT-737, through BCL-xL inhibition and synergy with ER stress inducers, triggers ovarian cancer death, offering promising strategies for overcoming chemoresistance in relapsed ovarian cancer.